| NCT ID | NCT06840977 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Matteo Clavarezza |
| Condition | Colon Adenocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 51 participants |
| Start Date | 2026-07-07 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 51 participants in total. It began in 2026-07-07 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this retrospective observational study, the case series of patients undergoing first-line treatment for metastatic colorectal adenocarcinoma with doublet fixed-dose and reduced-dose chemotherapy in combination with full-dose monoclonal antibody in patients aged 70 years or older is collected.
Eligibility Criteria
Inclusion Criteria: 1. Patients with metastatic colorectal adenocarcinoma not treated with any therapy in the metastatic phase. Previous (neo)-adjuvant treatment with fluoroderivatives with or without Oxaliplatin is permitted. 2. Age ≥ 70 years 3. G8 score ≥ 12 4. Patients with colorectal adenocarcinoma MSS 5. Patients with BRAF WT colorectal adenocarcinoma 6. Ability to understand and sign the informed consent form. Exclusion Criteria: 1. Patients with MSI tumours 2. Patients with BRAF V600E mutated tumours 3. Patients not eligible for doublet chemotherapy by clinical decision
Contact & Investigator
Matteo Clavarezza
PRINCIPAL INVESTIGATOR
E.O. Ospedali Galliera
Frequently Asked Questions
Who can join the NCT06840977 clinical trial?
This trial is open to participants of all sexes, aged 70 Years or older, up to 99 Years, studying Colon Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06840977 currently recruiting?
Yes, NCT06840977 is actively recruiting participants. Contact the research team at matteo.clavarezza@galliera.it for enrollment information.
Where is the NCT06840977 trial being conducted?
This trial is being conducted at Genova, Italy, Genoa, Italy.
Who is sponsoring the NCT06840977 clinical trial?
NCT06840977 is sponsored by Matteo Clavarezza. The principal investigator is Matteo Clavarezza at E.O. Ospedali Galliera. The trial plans to enroll 51 participants.